Genta/Aventis To Meet With FDA After Genasense NDA Withdrawal
This article was originally published in The Pink Sheet Daily
Executive Summary
The meeting will review key issues and identify next steps for Genasense development, Genta said. The company expects to release data from Phase III melanoma and leukemia studies throughout the year.